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Summary 
A pilot study exploring the examination of placental cord blood samples for mutant proteins with 
one-dimensional electrophoretic techniques is described. Although technical advances are such that the 
techniques employed in this study are now partially superceded, the practical problems encountered in this 
study would be typical of any monitoring program of this type. No mutations altering electrophoretic 
mobility among a battery of 51 different locus products were encountered in a total of 277 747 locus tests. 
When these data are combined with similar data from other studies, the mutation rate for electromorphs 
becomes 0.34 x 10-5/locus/generation. 
As the papers in the special number of Muta- 
tion Research illustrate, there now exist a number 
of sophisticated approaches to monitoring for 
genetic damage in somatic cells. Unfortunately, 
the value of these systems as predictive indicators 
for germ line damage transmitted to the next 
generation remains undetermined. An outstanding 
need in the field of human genetic monitoring is 
to build the necessary bridge between somatic and 
transmitted genetic endpoints, based insofar as 
possible on comparable indicators. Any really sig- 
nificant monitoring program of the future will 
undoubtedly pursue several different endpoints, 
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somatic and genetic, in an effort to build the 
bridges. 
Between 1976 and 1984 we developed methods 
for, and engaged in, a pilot study in the U.S.A. of 
one such possible component of a genetic moni- 
toting program, based on a combination of a 
search for charge-change variants with one-dimen- 
sional electrophoresis (1-D E) and for loss-of-ac- 
tivity variants by quantitative enzyme analysis. 
This may be considered the counterpart at the 
germinal level of the various efforts to develop 
techniques for identifying 'point mutations' in 
erythrocytes and lymphocytes. This study has now 
terminated; this presentation will undertake to 
summarize the data and lessons generated by the 
program. It is worth emphasizing at the outset 
that these 'lessons' will in many respects also 
apply to any similar study of mutation utilizing 
such other approaches as the examination of pro- 
teins by two-dimensional polyacrylamide gel elec- 
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trophoresis or of DNA by the various available 
methodologies. Preliminary references to this study 
have appeared in Neel et al. (1979, 1980) and 
Mohrenweiser (1981, 1983a). 
Protocol 
Justification of indicators 
The spectrum of spontaneous and induced mu- 
tation at the DNA level ranges from single base 
pair substitutions to dupfications, deletions, inver- 
sions, or translocations of large blocks of DNA, 
up to and including entire chromosomes. Electro- 
phoresis as currently practiced is designed to de- 
tect that fraction of nucleotide mutations which 
result in the substitution in a polypeptide chain of 
an amino acid whose charge differs from that of 
its predecessor, with retention of protein function. 
The quantitative enzyme assays should detect mu- 
tations resulting in complete or very significant 
loss of enzyme activity, the causes ranging from 
single nucleotide substitutions resulting in stop 
codons or unacceptable amino acid substitutions 
to deletions of varying size, both involving not 
only exons but introns and regulatory sites 
(Mohrenweiser, 1983b). In principle, electrophore- 
sis, in which the location of the protein is indi- 
cated either by a protein or an activity stain, 
should permit the identification of half-normal 
amounts of protein, but the extraneous sources of 
variation in the staining procedure and limitations 
of densitometric scanners have in the past limited 
the usefulness of this strategy. 
Different mutagens will produce different spec- 
tra of mutation. For instance, current evidence 
suggests that chemical mutagens will produce rela- 
tively more base pair substitutions than will ioniz- 
ing radiation while radiation may produce pre- 
dominantly deletions and rearrangements. Else- 
where we are reviewing this matter in some detail 
(Neel et al., in preparation). While the generaliza- 
tion is probably correct, we would argue that in a 
monitoring situation it is important to attempt to 
capture the entire spectrum of events, so that it is 
as necessary to establish what has not happened as 
well as what has. Thus endpoints which detect a 
wide variety of mutational events should be incor- 
porated into a proper monitoring effort. 
Source of samples 
There are of course a variety of sampling 
strategies for a population thought to be (or to 
have been) at risk of an increased mutation rate. 
Rarely, a population will be perceived as entering 
into a situation where mutation rates may be 
increasing; in this instance, if the population is 
sufficiently large, children studied for the occur- 
rence of mutation at the beginning of the program 
may serve as controls for the children born and 
studied later. More commonly, a population will 
have been subjected to a defined insult (atomic 
bomb explosion, nuclear power plant malfunction, 
inadvertent exposure to mutagenic chemical), and 
one must develop a suitable control group to the 
children born of exposed parents. One could, in a 
study employing biochemical indicators, use 
children of the same parents born prior to the 
insult as control on the children born after the 
insult, but even when biochemical (including 
DNA) variants in the heterozygous state are the 
indicators, it is possible there is negative selection 
against some variants, so that a retrospective study 
may be biased. A preferable alternative is a study 
where controls are identified and studied contem- 
poraneously with the children of exposed. In this 
design, the collection of blood samples from the 
placentae of newborn infants, after the cord has 
been severed, plus venous samples collected from 
both parents shortly preceding or following the 
delivery of the child, would appear to have much 
to recommend it; this was the procedure we have 
followed in a study of a normal population. 
In industrialized countries, most deliveries are 
concentrated in hospitals where such collections 
are convenient, and the monitoring of newborns 
leads to the identification of any increased muta- 
tion rate at the earliest possible moment. The 
principal disadvantage of this particular protocol 
is that if one needs to resample the child for any 
of a number of reasons, this may be quite difficult 
in a home setting during the first several years of 
life, the more so since the justification is scientific 
rather than medical. Given, in addition, the mobil- 
ity of the American public, and the operation of 
Murphy's genetic law number 12, which says that 
the parents of the child you most need to sample 
have just relocated in a distant setting, we con- 
clude that all studies should be performed without 
the expectation of second samples (although this 
possibility is not excluded). 
The University of Michigan Medical Center has 
a relatively small maternity service, averaging 
about 1800 deliveries/year. On an annual basis, 
the proportion of deliveries for which it was possi- 
ble to collect samples from both parents ranged 
from 25% to 75%. The high figure reflects the 
activities of a very committed Fellow in Perinatol- 
ogy (Dr. Linda Dunn), the low figure the lesser 
commitment by the house staff who followed her. 
An intermediate figure was obtained when the 
responsibility was delegated to the obstetric nurs- 
ing staff, and a small fee paid into an 'educational 
fund' for each completed trio. This latter ap- 
proach was adopted during the latter three- 
quarters of the study. 
The reasons for not achieving a higher comple- 
tion rate are various. All samples were collected 
with informed consent; not all couples wish to 
participate in a study which appears of no benefit 
to them or their child. The length of hospitaliza- 
tion following an uncomplicated delivery is now 
only about 3 days; it is not always possible to 
make contact with the father during this brief 
period. Finally, the collection of cord blood sam- 
ples has a rather low priority whenever the de- 
livery rooms are especially busy. The ethnic com- 
position of the final sample of 3456 infants was: 
88% Caucasians, 7% American Blacks, and 5% of 
Mongoloid, mixed or unknown ethnicity. Among 
the total sample, there were 210 sibpairs and 7 sib 
trios. There were also 7 apparently identical twins, 
of whom only one member of each pair has been 
included in the sample. 
The decision to collect (and process) samples 
from both parents at the time of their child's 
delivery was based on the following considera- 
tions. A variant with the electrophoretic mobility 
of a common polymorphism has a low probability 
of being a newly arisen mutation. Rare (i.e., non- 
polymorphic) variants have a much higher relative 
probability of resulting from a recent mutation, 
and the decision was reached to focus the search 
for mutations on these. Our preliminary experi- 
ence (Neel et al., 1978), and that of others, indi- 
cated that for any particular locus, such rare 
variants collectively were encountered as hetero- 
zygotes with a frequency of several per 1000 de- 
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terminations. Arbitrarily selecting a figure of 2 per 
1000 locus determinations, we calculated that if 
the number of loci under study ultimately num- 
bered 40, then the need for an examination of 
parental samples would arise in 100[1- (998/ 
1000)4°], or 7.7% of all infants studied. No com- 
parable preliminary data were available for the 
frequency of heterozygotes for enzyme deficiency 
variants in an unselected series, but their occur- 
rence in any frequency could only increase the 
need for family studies. It was 'guesstimated' that 
the collection and processing of parental samples 
close to the time of the child's birth would be 
more efficient in terms of time, costs, and availa- 
bility, than the attempt to collect samples from the 
parents of some 10% of the infants only after a 
variant had been demonstrated in the child. 
Accordingly, no child's sample was examined un- 
less specimens from both parents were also availa- 
ble. 
A number of variants were encountered which 
were apparently identical in phenotype with 
variants known to be low-frequency polymor- 
phisms within one of the two principal ethnic 
groups studied. The probability that any one of 
these represented a new mutation was very low. 
Unlike the common polymorphisms, however, 
which on any given working day would appear 
many times in the day's gels and so could be 
readily compared, these were encountered once or 
twice a week as isolated occurrences on a gel. We 
have accordingly elected to perform family studies 
on all those variants, as they were encountered (as 
well as the necessary comparison runs from time 
to time). They include the 2 type of AK, the C 
type of 6PGD, the C type of ACP, the D types of 
TF, the Michigan and A variants of CRPL, the 2 
type of PEPA, and the 2 and 3 variants of PEPD. 
Although some would argue that family studies on 
these variants in a protocol investigating mutation 
is unnecessary, we regard it as a conservative 
approach to the estimation of mutation rates. 
These family study data will also prove useful in 
the context of how the issue of non-paternity 
enters into a study of this type and will be intro- 
duced later. 
It was realized from the outset that this study 
was not of a magnitude to yield by itself definitive 
data on the frequency of mutation resulting in 
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electrophoretic variants. On the other hand, the 
data could be --  and have been - -  pooled with 
other appropriate data to yield such an estimate 
(Neel et al., 1986). A major emphasis of the Ann 
Arbor effort was the development and/or adapta- 
tion of biochemical methods for detecting germi- 
nal mutation, with the satisfactory methodologies 
to be introduced subsequently into the laborato- 
ries of the Radiation Effects Research Foundation 
in Hiroshima and Nagasaki, as the basis for the 
much larger study of the offspring of atomic bomb 
survivors (Neel et al., 1979, 1980). Finally, the 
data resulting from the study will eventually be 
incorporated into a treatment of the comparative 
genetics of a variety of ethnic groups. 
Methodology 
Blood samples were collected and processed as 
described by Neel et al. (1979) and Fielek and 
Mohrenweiser (1979). An aliquot of cells was re- 
tained in a glycerol-sorbitol mixture for blood 
typing (Weiner and Lourie, 1981). The electro- 
phoretic methodology has been previously de- 
scribed (Neel et al., 1980, 1986; Barrantes et al., 
1982; Long et al., 1986; Mohrenweiser and Neel, 
in preparation). Quantitative enzyme assay proce- 
dures were as described by Fielek and 
Mohrenweiser (1979) and Mohrenweiser (1981). 
Parentage verification 
When a rare variant in a child was not present 
in either parent, the child's blood sample and 
those of both parents were subjected to a battery 
of serological tests designed to detect a dis- 
crepancy between legal and biological parentage. 
In addition, certain of the loci examined for the 
occurrence of mutation are characterized by poly- 
morphisms useful in this context. The fact that the 
sample from the child was from a newborn infant 
precluded the use of several markers customarily 
used in such determinations: the subtypes of ABO, 
and the P, Lewis (erythrocyte), GM, KM, and HP 
systems. The serological systems routinely 
employed were ABO, MNS, RH, K, FY, JK; the 
biochemical typings yielded data on common 
polymorphisms of the ESD, GLO, ACP, AK, 
ADA, PGM1, GPT and GALT loci. The probabil- 
ity of excluding a Caucasoid male incorrectly 
identified as the father of a given child was 0.88 
with this battery. The corresponding exclusion 
probability for an American Black was 0.82. In 
the event of a putative mutation in which there 
was no exclusion with this battery, further efforts 
at exclusion would involve isoelectric focusing for 
the subtypes of PGM1 and GC, and HLA typings. 
The latter would involve recontacting the family 
since aliquots of leukocytes were not routinely 
stored. If the family was recontacted when the 
infant was at least 6 months old, the tests men- 
tioned above as impossible in a newborn could 
also be performed. 
In addition, in order to set a prior probability 
of biological-legal parentage discrepancies in this 
sample, over a period of 3 years, 220 randomly 
selected trios of samples (father, mother, and child) 
were subjected to the above-enumerated typings. 
Such prior probabilities are necessary to any 
calculation of the relative probabilities of an ap- 
parent mutation being the result of an undetected 
parentage exclusion rather than a true mutation. 
Among this sample, there were 196 Caucasoid 
trios, 18 American Black trios, 3 mixed 
Caucasoid-Black, and 2 for whom race was not 
indicated. 
R e s u l t s  
Variant frequencies 
The total number of locus tests for electro- 
phoretic variants and the frequency of rare variants 
is shown in Table 1. Allowance has been made for 
loci which are duplicated (HBA1, HBA2 and 
HBG1, HBG2) and proteins which are composed 
of two or more polypeptides (HB, LDH, ESA). A 
total of 51 loci are represented in the data. The 
varying number of determinations from locus to 
locus reflect the phasing in of additional systems 
as the study progressed. The number of variants 
indicated for each locus must in general be an 
underestimate, since no single electrophoretic sys- 
tem will detect all of the charge-change variants of 
a given protein. Some of the more interesting 
variants in this series have already been described 
[CP - -  Mohrenweiser and Decker (1982); TPI --  
Asakawa and Mohrenweiser (1982); GOT --  
Wurzinger and Mohrenweiser (1982); GPI --  
Mohrenweiser et al. (1987); G6PD --  
Mohrenweiser and Fielek (in preparation)]; a 
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TABLE 1 
FREQUENCIES OF RARE ELECTROPHORETIC VARIANTS IN A SERIES OF ELECTROPHORETIC DETERMINATIONS 
ON ERYTHROCYTE AND PLASMA PROTEINS 
Enzyme EC No. Abbrev. Caucasians Am. Blacks Total a 
(variants/ (variants/ (variants/ 
determs.) determs.) determs.) 
Acetaldehyde dehydrogenase 1.2.1.3 ALDH 0/1256 0/99 0/1431 
Acid phosphatase 1 3.1.3.2 ACP1 2/3026 4/256 7/3450 
Adenosine deaminase 3.5.4.4 ADA 0/3007 0/253 0/3436 
Adenylate kinase 1 2.7.4.3 AK1 4/3003 0/253 4/34320 
Albumin ALB 2/2743 0/221 2/3118 
Apolipoprotein A1 APOA1 1/1076 2/76 3/1220 
Carbonic anhydrase-1 4.2.1.1 CA1 0/676 2/73 2/784 
Carbonic anhydrase-2 4.2.1.1 CA2 0/890 0/93 0/1031 
Ceruioplasmin CRPL 2/2938 3/246 5/3348 
Diaphorase 1.6.*.* DIA 5/696 0/47 5/790 
Enolase-1 4.2.1.11 ENO1 0/1257 0/99 0/1432 
Esterase A-1 3.1.1.1 ESA1 3/3020 1/255 4/3443 
Esterase A-2 3.1.1.1 ESA2 1/3020 0/255 1/3443 
Esterase A-3 3.1.1.1. ESA3 0/3020 0/255 0/3443 
Esterase A-C 3.1.1.1 ESAC 1/3020 0/255 1/3443 
Esterase B 3.1.1.1 ESB 0/1848 0/144 0/2098 
Esterase D 3.1.1.1 ESD 0/3028 0/255 0/3451 
Fumarate hydratase (fumarase) 4.2.1.2 FUM 0/1071 0/78 1/1214 
Gal-l-phosphate uridyl transferase 2.7.7.12 GALT 1/2969 0/249 1/3384 
Glutamate-oxaloacetic transaminase(S) 2.6.1.1 GOTS 11/3024 3/255 17/3447 
Glucose-6-phosphate dehydrogenase 1.1.1.49 G6PD 5/2485 0/197 6/2826 
Glucosephosphate isomerase 5.3.1.9 GPI 18/3007 0/253 18/3427 
Glutamate-pyruvate transaminase(S) 2.6.1.2 GPTS 6/1301 1/101 7/1481 
Glyoxalase-1 4.4.1.5 GLO1 0/1402 0/126 0/1608 
Hemoglobin A-1 HBA1 0/3007 3/253 3/3427 
Hemoglobin A-2 HBA2 0/3007 0/253 0/3427 
Hemoglobin B HBB 1/2984 1/252 2/3403 
Hemoglobin GA HBGA 1/3007 0/253 1/3427 
Hemoglobin GG HBGG 0/3007 0/253 0/3427 
Hexokinase-1 2.7.1.1 HK1 2/2938 0/248 2/3354 
Hexokinase-2 2.7.1.1 HK2 0/3007 ,)/254 0/3429 
Inosine triphosphatase 3.6.1.19 ITPA 0/1256 0/99 0/1431 
Isocitrate dehydrogenase(S) 1.1.1.42 ICDS 2/2915 0/242 2/3317 
Lactate dehydrogenase A 1.1.1.27 LDHA 2/3007 4/253 6/3427 
Lactate dehydrogenase B 1.1.1.27 LDHB 1/3007 0/253 2/3427 
Malate dehydrogenase(S) 1.1.1.37 MDHS 0/3007 0/253 0/3427 
Nucleoside phosphorylase 2.4.2.1 NP 3/3019 0/256 3/3443 
Peptidase A 3.4.11.* PEPA 5/3020 0/256 5/3444 
Peptidase B 3.4.11.* PEPB 7/3025 2/257 9/3450 
Peptidase C 3.4.16.* PEPC 9/2832 1/236 10/3226 
Peptidase D 3.4.13.9 PEPD 3/2834 1/238 4/3230 
Phosphoglucomutase-1 2.7.5.1 PGM1 4/3028 0/257 4/3453 
Phosphoglucomutase-2 2.7.5.1 PGM2 4/3027 2/257 6/3452 
Phosphogluconate dehydrogenase 1.1.1.44 PGD 2/3006 0/252 2/3425 
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TABLE 1 (continued) 
Enzyme EC No. Abbrev. Caucasians Am. Blacks Total ~ 
(variants/ (variants/ (variants/ 
determs.) determs.) determs.) 
Phosphoglycerate kinase 2.7.2.3 PGK 0/2104 0/161 0/2385 
Inorganic pyrophosphatase 3.6.1.1 PP 0/684 0/72 0/793 
Prealbumin PALB 0/887 0/53 0/1004 
7-s-r-Globulin BG7S 0/693 0/45 0/783 
Transferrin TF 49/2938 0/246 49/3348 
Triosephosphate isomerase 5.3.1.1 TPI 2/3005 0/253 2/3425 
Uroporphyrinogen synthetase 4.3.1.8 URO 6/1989 0/192 6/2307 
Totals 165/123023 30/10291 202/140259 
a Includes the miscellaneous ethnic groups as well. 
comprehensive description of the electrophoretic 
findings, with an indication of the 'rare variant 
structure' of each locus, will be forthcoming 
(Mohrenweiser and Neel, in preparation). There 
were 202 rare variant phenotypes in 140259 
determinations. Since each determination involves 
the product of 2 genes (except for the sex-linked 
loci G6PD and PGK), this amounts to 202 variants 
in 277 747 locus tests. The diffference in variant 
allele frequency between Caucasoids (165/123 023) 
TABLE 2 
FREQUENCIES OF ACTIVITY VARIANTS FOR A SERIES OF 12 ENZYMES SELECTED FOR RELATIVELY LOW 
COEFFICIENTS OF VARIATION 
Further explanation in text. 
Enzyme EC No. Abbrev. Caucasians Am. Blacks Total b 
(variants/determs.) (variants/determs.) (variants/deterrns.) 
Adenylate kinase 2.7.4.3 AK 2/1797 0/174 3/2078 
Diphosphoglycomutase 2.7.5.3 DPGM 2/1160 0/88 3/1312 
Enolase-1 4.2.1.11 E N O 1  6/1166 1/88 10/1321 
Glucose-6-phosphate dehydrogenase 1.1.1.49 G6PD 15/1812 (1) ~ 21/174 (10) ~ 38/2092 
Glucosephosphate isomerase 5.3.1.9 GPI 5/1795 0/174 5/2076 
Glut amate-oxaloacetic transaminase(S) 2.6.1.1 GOTS 2/1666 1/167 3/1935 
Glyceraldehyde dehydrogenase 1.2.1.12 GAPD 0/1104 0/87 0/1255 
Lactate dehydrogenase 1.1.1.27 LDHB 0/1819 0/176 0/2103 
Malate dehydrogenase 1.1.1.37 MDH 1/1819 1/176 2/2103 
Phosphoglycerate kinase 2.7.2.3 PGK 0/1819 0/176 0/2103 
Pyruvate kinase 2.7.1.40 PK 18/1819 4/176 23/2103 
Triosephosphate isomerase 5.3.1.1 TPI 9/1796 8/174 18/2077 
Totals 60/1-i-ff5~ 36/1830 105/22 558 
a 10 of 21 are G6PD A-  and 1 of 15 is a C-  variant. 
b Includes the miscellaneous ethnic groups as well. 
and Blacks (30/20 380) is significant (X 2 = 16.10, 
df = 1, p < 0.001). 
The tests for activity variants are summarized 
in Table 2. There were 19 572 determinations dis- 
tributed over 12 enzymes on samples from 
Caucasoid infants, or 35513 locus tests; these 
yielded 60 variants. The corresponding figure for 
Blacks was 1830 determinations or 3310 locus 
tests, yielding 26 variants. The total is 95 variants 
in 40921 locus tests. (The G6PD A-  variant in 
Blacks is not included in these numbers.) Again, 
the frequency of variants is higher in Blacks (X 2 = 
52.07, df= 1, p < 0.001). This is true even if the 
TPI 1 ° variant of Blacks (Mohrenweiser and 
Fielek, 1982) is excluded from the calcuation. 
Genetic discrepancies between child and parents 
Two kinds of genetic discrepancies must be 
distinguished in this material, namely, those caused 
by 'clerical' error in the delivery room or labora- 
tory, and those which have a biological basis. In 
the total series there were 23 trios in which the 
alleged newborn failed to exhibit fetal homo- 
globin. Nine of these were clustered in such a way, 
and occurred over such a brief time span, that it 
was apparent that a new junior-level technician 
(who was shortly separated from the study) was 
simply not up to the task of sample processing. 
The remaining 14 were apparently due to errors of 
labeling in the primary collection process. Of 
course none of these trios is included in the series, 
although typings revealed that some of them could 
have been salvaged. 
With these exclusions, among the 202 variants 
in 140259 determinations there were 4 which 
occurred in a child, neither of whose parents 
exhibited the variant. In 2 of these cases there was 
a 2- or 3-system paternity exclusion based on the 
routine battery of tests described earlier. In 1 case, 
there was no exclusion with the routine battery, 
but a 2-system exclusion was obtained when the 
typings were extended to include isoelectric focus- 
ing of PGM1 and GC. (Both systems yielded an 
exclusion, ) The remaining variant was of the sex- 
linked trait G6PD, where a mother's erythrocyte 
lysate repeatedly failed to show, on standard elec- 
trophoresis, a G6PD variant with reduced activity 
(12% of normal) observed in her son. G6PD activ- 
ity was, however, reduced in the mother (52% 
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normal). Fresh blood samples were obtained from 
the mother and son, as well as the father and 2 
sisters of the proband. Now the variant was 
observed in the mother's leukocytes, and faintly, 
in both the hemolysate and leukocyte cytosol of 
one of the daughters. We conclude that the mother 
is heterozygous for the variant but because of its 
reduced activity and the small anodal shift in the 
mobility of the variant isozyme, it could not be 
detected in the heterozygous mother. We are thus 
left with no putative mutations in this material. 
There were also no putative mutations in the 
series analyzed for quantitative variation. 
Parentage exclusions in normative series 
Two of the sample (trio) interchanges men- 
tioned earlier were found among the 196 Caucasoid 
trios in which normative paternity testing was 
performed, and were excluded from the series. 
There are thus left 218 randomly selected trios 
subjected to paternity exclusion studies, for which 
there were no exclusions. 
There is available from this study an additional 
estimate of the frequency of non-paternity in this 
data set. Each family study for a rare variant is in 
effect a test either for the occurrence of non- 
paternity or mutation. As noted, there were 202 
such variants. In addition, there were 303 family 
studies with reference to the low-frequency poly- 
morphisms, as described earlier. Among the latter, 
there were 4 instances in which the variant was 
not found in either parent and family studies 
resulted in paternity exclusions. Among the former, 
as described in the preceding section, there were 3 
exclusions. The exclusion frequency is thus 7/527 
or 1.33 + 0.50%. 
Given the knowledge that there are paternity 
exclusions in this series, we can ask what frequency 
of paternity discrepancies can be excluded at the 
5% probability level in the normative series of 
paternity studies, in which no exclusions were 
actually observed. With a one-tailed probability 
test, this is 1.4%. There is thus no conflict between 
the results of the normative series for paternity 
exclusions and the frequency observed in the 
family studies of the 525 electrophoretic mobility 
variants just described. There seems no reason 
why the two series cannot be combined to yield a 
best estimate of the frequency of extramaritally 
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conceived children in this study; the resulting 
frequency is 7//748, or 0.94 + 0.35%. Correction 
for the fact that our routine exclusion procedures 
were only 88.3% effective brings that figure to 
1.11 + 0.38%. 
Discussion 
We will first discuss some of the facts generated 
by this study, and then turn to a consideration of 
the future of this approach as a component in an 
actual monitoring situation, most likely involving 
a study of two samples of newborn infants or 
older children, one set born to parents thought to 
be at mutagenic risk, the other to a properly 
matched set of non-exposed parents. 
The average allele frequency of rare variants in 
this series was 0.8 per 1000 locus tests. This figure 
cannot be directly compared with any other be- 
cause of differences in the loci studied in the 
various series. The most nearly comparable data 
come from the studies on the genetic effects of the 
atomic bombs in Japan, where a rare variant 
frequency of 0.8 per 1000 locus tests was also 
obtained among the children of parents not ex- 
posed to the radiation of the atomic bombs (Neel 
et al., 1986). What is important in the present 
context, for calculating work load, is that for any 
given locus, about 1 in 500 determinations will 
result in a finding that must be followed by family 
studies. With 50 loci under scrutiny, this implies 
that about 1 in 10 children would exhibit a finding 
requiring family studies. If one also did family 
studies on the least common polymorphisms for 
the reasons stated above, about 1 in 5 children 
would require a family study. 
As noted earlier, family studies were not per- 
formed on the common polymorphisms. This con- 
vention carries with it the risk of missing a mu- 
tation whose phenotype mimics a common poly- 
morphism. Elsewhere we have calculated that the 
underestimation of mutation rates which results 
from this omission should be about 10% (Neel et 
al., 1983). On the other hand, undertaking a family 
investigation to test whether a common polymor- 
phism was the result of a mutational event in a 
parent would have increased the work load of 
family studies by an order of magnitude basd on 
the actual polymorphism frequencies in these data. 
A known 10% error is deemed acceptable under 
these conditions. 
The frequency of paternity exclusions in this 
material appears unusually low. We have con- 
ducted two other studies which yield data on the 
frequency of extramarital conceptions among 
children born in the state of Michigan. In an 
analysis of a series of nuclear families from the 
lower portion of the state of Michigan, studied 
between 1956 and 1964 because of the occurrence 
of a potentially lethal disease in a child (Gersho- 
witz and Neel, 1965), Schacht and Gershowitz 
(1963) calculated that 1.48 _+ 0.32% of 1417 
Caucasoid children were conceived extramaritally, 
the corresponding figure for 523 Black children 
being 9.94 _4-1.31%. In a second study which in- 
volved a large series of typings of blood samples 
drawn in 1965 from Caucasoid individuals resid- 
ing in a Michigan town with approximately 10000 
inhabitants, we estimated that 3.82 _+ 0.34% of the 
children for whom there were typings on the 
nuclear family were conceived extramaritally (Sing 
et al., 1971). Both of these studies included the 
total available sibship. The frequency of detected 
extramarital conceptions was significantly higher 
among first-born children, suggesting the possibil- 
ity that these exclusion figures are biased upwards 
by children actually conceived before marriage. 
The circumstances of the present study would 
imply that the children from whom samples were 
obtained were predominantly conceived in 
wedlock; further, in the relatively sophisticated 
town of Ann Arbor, parents might be reluctant to 
give the necessary informed consent if there were 
doubts concerning paternity. The earlier figures 
may also be inflated to some small extent by 
typing errors, since in both these studies 1-system 
exclusions (always based on duplicate typings) 
were accepted, and some laboratory error cannot 
be excluded. We thus are unwilling to engage in 
statistical contrasts between the various series. Let 
us assume, that in the U.S.A., the frequency of 
extramarital conceptions is between 0.01 and 0.02. 
As we have seen, the probability such a conceptus 
would receive a rare variant from the father is 
approximately 0.001. Finally, with a combination 
of the appropriate blood typings and HLA de- 
terminations, the probability of non-detection of 
an extramaritally conceived child is approximately 
0.01 (Neel et al., 1986). Thus the probability that 
an apparent mutation is actually due to an un- 
detected extramarital conception in our setting is 
between 0.01 × 0.001 x 0.01, or 1 x 10 -7, and 0.02 
× 0.001 × 0.01, or 2 × 10 -7. 
There were no mutations in 276 747 locus tests 
for electromorphs. Among the 3 studies which 
may be considered comparable to this one, Harris 
et al. (1974) reported no mutations in 133478 
locus tests on residents of the United Kingdom, 
Altland et al. (1982a, b) encountered 1 mutation 
among = 225000 tests on newborns in West 
Germany, and we encountered 3 mutations in 
539170 locus tests on children born in Hiroshima 
and Nagasaki to parents who did not receive 
excess radiation at the time of the atomic bombing 
[i.e., the 'controls' of a study on the genetic effects 
of the bombs (Neel et al., 1986)]. Our present 
findings are consistent with the results of these 
other studies; with this paper, the current estimate 
of the spontaneous rate with which mutation gives 
rise to electromorphs becomes 0.34 x 10-5/  
locus/generation. Since only one-third to one half 
of nucleotide substitutions in exons result in an 
electrophoretic variant, these findings correspond 
to a nucleotide rate per (exon) locus per genera- 
tion of approximately 1 x 10 -5, and per nucleo- 
tide per generation, of approximately 1 x -8. (This 
latter calculation assumes that the average poly- 
peptide included in this study requires 1000 exon 
nucleotides for its specification.) This estimate 
does not include gene-inactivation mutations or 
small duplications and deletions. The calculation 
of the previous paragraph suggests that false mu- 
tations resulting from undetected extramarital 
conceptions should make a relatively small contri- 
bution to this estimate. Inasmuch as no sponta- 
neous mutations resulting in loss of enzyme activ- 
ity have as yet been encountered, a rate cannot be 
calculated for this phenomenon; from experimen- 
tal studies we surmise that such mutations will at 
least equal in frequency the above-mentioned cor- 
rected rate for nucleotide substitutions. 
It is apparent that a search for an increase in 
mutation rates based on electromorphs and loss- 
of-functional-product mutations will involve large 
numbers of observations and be quite laborious, 
the size of any study of course depending on the 
desired precision. A guiding consideration in the 
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future for a monitoring program must be to obtain 
more data per individual. This is because in any 
actual study of the offspring of potentially mutag- 
enized individuals, the 'front end' costs involved 
in the initial contacts and obtaining the blood 
samples are apt to make a very significant contri- 
bution to the total cost of the study, and more 
importantly the number of offspring born to 
mutagenized parents will - -  it is to be hoped - -  
usually be so small that as much as possible must 
be learned from each offspring. In this final sec- 
tion, we would like to consider briefly the pro- 
spects for obtaining more data with the ap- 
proaches presented in this paper and then contrast 
these prospects with those inherent in two-dimen- 
sional polyacrylamide gel electrophoresis (2-D 
PAGE), plus those arising from the first glimmer- 
ings of a DNA approach. 
With respect to improvements in the 1-D E 
technologies employed in this study, the most 
significant advances would include the increased 
utility of isoelectric focusing, the increased availa- 
bility of antibodies to a large number of proteins, 
and improved instrumentation for densitometric 
analysis. The increased utility of isoelectric focus- 
ing stems from the availability of precast gels, the 
ability to construct gels with gradients designed 
for maximum sensitivity, and automation of 
several steps (Altland et al., 1982a, b; Chrambeck 
et al., 1980; Vogel and Altland, 1982). For a study 
to detect mutations which alter the electrophoretic 
mobility of proteins, isoelectric focusing has the 
advantage, for many proteins, of being the most 
sensitive separation technique. Therefore, the 
minimum number of amino acid interchanges will 
be missed. It also has significant potential for 
automation. Isoelectric focusing will not totally 
replace other electrophoretic methods using poly- 
acrylamide, starch, cellulose acetate, etc., as some 
proteins are denatured or inactivated at their iso- 
electric point. 
Historically, most proteins have been identi- 
fied, following electrophoresis, by standard pro- 
tein stains if they were among the prevalent pro- 
teins in the sample or by a functional assay, i.e., 
enzymatic activity. The availability of antibodies 
has increased the number of proteins which can be 
studied by electrophoresis (Chapuis-Cellier et al., 
1980; Tsang et al., 1983). The utilization of im- 
374 
munochemical techniques could potentially dou- 
ble the number of gene products which could be 
studied in routine blood samples. For any future 
program involving 1-D E, it would probably be 
advisable to employ the techniques of Altland to 
the extent possible, supplemented by those em- 
ployed in this study when necessary. 
New instruments devoted to densitometry, such 
as the LKB XL Laser Densitometer, have im- 
proved the technical feasibility of quantifying the 
staining intensity of proteins previously separated 
by electrophoresis. The assay could be a func- 
tional assay, as for enzymes, or could be linked to 
the immunological detection methods. This would 
have an advantage, in that proteins with similar 
enzymatic activities, but products of different loci 
(e.g. PGM 1 and 2), could now be quantified. It 
will be necessary for the sample application steps 
to be more accurately controlled if the proteins on 
the gels are to be analyzed quantitatively, al- 
though, as several enzymes/proteins are stained 
on each gel, it will be possible to compare the 
staining intensity of one enzyme to several others 
as references in the search for 50% staining inten- 
sity. 
As regards the quantitative enzyme assays 
whose results are described in this paper, it should 
now be possible to increase the battery from the 
12 we have employed to at least 25-30 erythrocyte 
enzymes. A series of recent developments in 
quantitative enzyme analyses (e.g., better com- 
puter interfacing and refined sample allocation 
procedures) would increase the rate of data gener- 
ation using the quantitative techniques employed 
in generating the data described in this paper. 
Thus, the combination of new methods and new 
instruments would increase the data base per sam- 
ple and reduce the cost per determination. The 
constraint of limited biological variation among 
individuals is important for quantitative analysis 
irrespective of the analytical technique employed. 
Therefore quantitative analysis will generally be 
restricted to the proteins of blood cells rather than 
plasma as quantitative changes in plasma proteins 
generally reflect physiological and/or  pathological 
conditions rather than genetic regulation. 
Turning now to the potential applications of 
2-D PAGE to monitoring, we have recently laid 
out in some detail not only the current laboratory 
procedures (Neel et al., 1984) but the current state 
of computer algorithms designed to read these gels 
with minimal operator intervention (Skolnick and 
Neel, 1986). The ability of this technique to detect 
electrophoretic variants has been adequately dem- 
onstrated (summary in Takahashi et al., 1987). 
For reasons which remain debatable, the amount 
of genetic variation encountered in these gels is 
somewhat less than with 1-D E, a fact which must 
be borne in mind in planning any program to 
study mutation rates. The principal deficiency in 
the technique at present is the failure thus far, in a 
screening mode (single densitometric readings of 
single gels with light optics), to develop a battery 
of spots in which one can distinguish with the 
necessary accuracy stained polypeptides with only 
50% of the normal amount of protein (i.e., 'null' 
heterozygotes). There is, however, promise that 
this problem can be met with the development of 
thin-layer gels (GiSrg et al., 1985) and laser 
densitometry, at least for a subset of the quantita- 
tively less variable proteins. The principal draw- 
back with laser densitometry as currently available 
is the slow reading time. 
With respect to cost, our current best estimate 
is that the cost, per research-quality 2-D gel scored, 
is $20.00. In a monitoring system depending on 
blood samples, gels can be prepared from plasma, 
erythrocytes, platelets, lymphocytes, and polymor- 
phonuclear leukocytes. There is an as yet unde- 
termined overlap in the polypeptides visualized in 
the latter 3 preparations. Let us assume that there 
are an average of 100 different proteins which can 
be scored with the requisite accuracy in prepara- 
tions of each of the first 3 above-mentioned blood 
components. Then the cost per determination is 
$0.20. However, with allowance for the 'front end' 
costs, the costs per determination would be more 
like $0.30. This cost does not include the data 
management system, the expense of which will 
vary with the size of the project. An important 
potential advantage of 2-D PAGE over 1-D E is 
the possibility that both qualitative and quantita- 
tive variation for a large number of proteins can 
be studied in the same 2-D gel. Our present prac- 
tice in the study of genetic variation in 2-D gels is 
to make preparations on the mother and father of 
each subject simultaneously with the preparation 
on the child (cf. Neel et al., 1984). If this were 
continued indefinitely, it would triple the number 
of gels necessary to a monitoring program. It is, 
however, our expectation to develop a standard 
2-D map which includes the positions of polymor- 
phic variants, in which case preparations from the 
parents would be necessary only when a rare 
variant was encountered, that is in approximately 
1 of 4 families. 
It is of some interest to attempt to cost out an 
appropriately sized study. Both the estimates of 
cost per determination for 1-D E and 2-D PAGE 
will decrease to some extent in the future, with 
automation and other technical improvements, but 
we must work with present costs. Let us assume a 
situation in which only 1 parent had been exposed 
to a mutagen. If, for instance, one required a 
minimum of 2 000 000 locus tests in the children of 
exposed and the same number for controls (the 
latter requiring, since both loci are relevant, half 
as many persons), the cost of a 2-D PAGE study 
is roughly $900 000 on the assumption that routine 
gels on the parents will become unnecessary in the 
future. But since these costs do not include the 
various legitimate types of incidental overhead 
expenses, or the data-handling costs, or the special 
biochemical studies which might be undertaken to 
verify a mutation, the cost should at least be 
doubled to approximately 2 million. 
The cost for the combined 1-D electrophoetic 
and quantitative enzyme assays in the Ann Arbor 
study is $0.75 per locus test or $1.50 per de- 
termination. Thus, to complete a study as de- 
scribed above using 1-D electrophoresis and 
quantitative assays would cost approximately 3 
million dollars. As one goal of this study was to 
develop methods which would contribute to the 
program at the Radiation Effects Research 
Foundation, that is, a monitoring program, maxi- 
mizing the data base per proband was an im- 
portant consideration when the effort was ini- 
tiated. The estimated cost per test completed in 
this study includes not only laboratory personnel 
and reagent costs but also includes $15 as the cost 
of obtaining the sample and the cost, including 
personnel, for data storage and management. As 
noted, utilizing the methodology developed by 
Altland et al. (1982a, b) where feasible, could 
substantially decrease costs but by an amount 
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which cannot be estimated. Modifying the meth- 
ods, for example, to incorporate more isoelectric 
focusing techniques and adding new loci studied 
by immunochemical detection methods, would not 
have a significant impact on cost per test but 
would increase the data obtained for each prob- 
and as incorporation of the automation for elec- 
trophoresis or utilization of the new generation of 
quantitative enzyme analyzers could reduce the 
personnel cost as the screening becomes more 
efficient. 
In any future study we would suggest serious 
consideration be given to the routine preservation 
of some or all of the leukocyte fractions, for 
reasons ranging from the possibility of additional 
genetic tests to establishing cell lines for special 
studies when indicated. This would of course sub- 
stantially increase the initial costs of the study. 
There are first glimmerings of DNA systems 
for the study of mutation (cf. Delehanty et al., 
1986). These technologies are so early, and ad- 
vancing so rapidly, that it is premature to attempt 
to derive even soft cost figures. However, it may 
be pointed out that a single, average 2-D gel, 
especially if accurate spot quantification becomes 
available, would reflect the results of certain types 
of mutation at 200000 nucleotides (100 spots × 2 
alleles x 1000 exon nucleotides), and so can pro- 
vide a standard against which to measure the 
efficiency of a DNA system. 
In concluding, we would like to emphasize that 
even with the technical developments which may 
confidently be anticipated, the study of germinal 
mutation, whether by the techniques mentioned in 
this paper or by cytogenetic or clinical ap- 
proaches, will remain laborious and demanding 
for the immediate future. There are no potentially 
dramatic short-cuts in sight. But without these 
studies, the predictive value of somatic cell studies 
will forever remain obscure. Once the necessary 
'bridges' have been built between the somatic and 
genetic endpoints, one may no longer need the 
very demanding germ-line studies, but without 
these bridges, the predictive value of somatic cell 
studies for genetic damage for future generations 
remains at best dubious but at worst, a source of 
free-floating anxiety to already concerned people 
who deserve better. 
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